Wipfli Financial Advisors’s TherapeuticsMD TXMD Stock Holding History

Wipfli Financial Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$0	Buy	+22	New	+$178	﹤0.01%	2619

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Wipfli Financial Advisors's TXMD Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in TherapeuticsMD (TXMD) in Q3 2022: 22 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2619 among its holdings.

43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

Wipfli Financial Advisors held 22 shares of TherapeuticsMD worth $0 as of Q3 2022.
TherapeuticsMD was a new Wipfli Financial Advisors position in Q3 2022.
TherapeuticsMD made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2619 holding.
43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.